Finistere II Fund, LP
Finistere II Fund, LP
Finistere Ventures is currently raising of a new fund which will focus on its recognized leadership in technology investing to address agricultural markets including Food, Energy and Sustainability. The new fund will build on the success of Finistere’s current funds,and will be called the Finistere II Fund, LP. It is expected to close in the first half of 2013. Information for prospective investors can be obtained by contacting us at firstname.lastname@example.org
Finistere Ventures has two active Funds: FINISTERE – CHICAGO
PARTNERS I and
FINISTERE – OCEANIA PARTNERS I.
The Finistere Ventures active Funds are closed and have been in an active investment phase since their inception in 2005. These Funds are continuing to be invested and plan to remain in their active phase through 2010. Our approach is to co-invest our existing pools of funding in opportunities that fit with our investment strategy.
Our investment strategy is outlined on our Investment Strategy section.
At Finistere Ventures, we focus on early stage investments in “Food, Energy and Health” and are typically involved in the initial venture financing of early stage and growth financing of companies involved in agricultural innovation, and medical devices and diagnostics. We believe that these are the sectors where our team and networks offer our investors the best opportunities for venture returns.
In principle, we do not invest in Public Companies, or in mature project financing opportunities that are better served by the Private Equity industry.
The Food, Energy & Health sectors are broad areas within which we specifically focus on Agricultural innovation - for example, Agbiotech, agritech, precision agriculture and renewable energy & materials from biomass - and Medical Devices & Diagnostics - particularly in areas such as cardiovascular, neurological and increasingly in growth areas such as ophthalmology.
Finistere Ventures operates principally in the US market, but will invest in sourcing technologies from outside the US where there is an opportunity to migrate and develop the company towards an exit in the US market.
From an investment standpoint, we see the Agricultural innovation opportunities, biomass-based renewables and medical devices markets involving less risk than other segments of Life Sciences such as the human therapeutics industry. Both Agricultural innovation opportunities and medical devices have relatively shorter product development time lines, fewer regulatory hurdles and lower capital costs. However, they are consolidated industries with large players that invest significantly to acquire new technologies from smaller start-ups. Currently, both the Agricultural innovation opportunities and medical devices industries are in an investment upswing that will last well in to the next decade, offering fertile ground for new venture investment.
Ultimately, we are looking to provide exits and returns for our investors within five years of an investment, which we believe is in alignment with the opportunities available in our targeted sectors, and is appropriate to the venture investment model returns we expect for our Investors.